iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of iBio (NASDAQ:IBIO) from a sell rating to a hold rating in a research report released on Saturday morning.

A number of other analysts also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research report on Monday, December 29th. Lifesci Capital upgraded shares of iBio to a “strong-buy” rating in a research report on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, iBio presently has a consensus rating of “Buy”.

iBio Stock Down 8.1%

NASDAQ IBIO opened at $2.82 on Friday. The business’s fifty day simple moving average is $2.25. The company has a market cap of $97.40 million, a PE ratio of -2.82 and a beta of 1.26. iBio has a one year low of $0.56 and a one year high of $6.89.

iBio (NASDAQ:IBIO) last posted its quarterly earnings data on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.